Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients

Giorda, Carlo; Forlani, Gabriele; Manti, Roberta; Mazzotti, Arianna; Cosmo, Salvatore De; Rossi, Maria Chiara; Nicolucci, Antonio; Bartolo, Paolo Di; Ceriello, Antonio; Guida, Pietro; Tartaglino, Barbara; Russo, Giuseppina T.

doi:10.1016/j.diabres.2017.10.023

Cited by 22 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a significant correlation between steatosis and FBG (p=0.023) in group IA as in Table (9) and Fig. (4).…”

Section: As Regard Fbgmentioning

confidence: 63%

“…On the other hand Giorda et al, [9] about 56.6% of the studied groups were males. While Dobrin et al, [13] investigated 62 patient 20 females & 42 males.…”

Section: Discussionmentioning

confidence: 74%

“…Also according to Table (9) and Fig. (3) there was a significant correlation between steatosis and BMI in group IA (p=0.037).…”

Section: As Regard Fbgmentioning

confidence: 67%

“…(1) there was a significant correlation between steatosis and triglycerides (TG) in group IA (p=0.016). There was also a significant correlation between steatosis and total cholesterol in group IA (p=0.001) according to Table (9) and Fig. (2).…”

Section: As Regard Fbgmentioning

confidence: 68%

“…It encompasses a broad spectrum of chronic liver conditions ranging from simple hepatic steatosis (nonalcoholic fatty liver) to nonalcoholic steato-hepatitis, with increased risk of progression to cirrhosis and hepatic cancer [7] . Moreover, excess mortality from chronic liver disease in type 2 diabetes ranks with excess risk of death from cardiovascular complications [8] , suggesting that end-stage liver disease should be added to the list of known complications of diabetes [9] .…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

Ayad¹,

Soliman

Esheba³

et al. 2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

show abstract

“…There was a significant correlation between steatosis and FBG (p=0.023) in group IA as in Table (9) and Fig. (4).…”

Section: As Regard Fbgmentioning

confidence: 63%

“…On the other hand Giorda et al, [9] about 56.6% of the studied groups were males. While Dobrin et al, [13] investigated 62 patient 20 females & 42 males.…”

Section: Discussionmentioning

confidence: 74%

“…Also according to Table (9) and Fig. (3) there was a significant correlation between steatosis and BMI in group IA (p=0.037).…”

Section: As Regard Fbgmentioning

confidence: 67%

Section: As Regard Fbgmentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

Ayad¹,

Soliman

Esheba³

et al. 2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

show abstract

Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease

Colletta¹,

Colletta

Placentino³

2020

J Diabetes Metab Disord

View full text Add to dashboard Cite

Background Nonalcoholic fatty liver disease (NAFLD) is common in both prediabetic patients and healthy overweight individuals, yet it remains understudied. This study investigates the effects of hepatic steatosis on fibrosis and evaluates the major predictors of liver injury in prediabetes and whether this damage is reversible with Mediterranean diet and administration of the nutraceutical silymarin. Methods First, a case-control study was conducted in which 212 patients with prediabetes, not known to have NAFLD, and 126 healthy controls underwent clinical evaluation, transient elastography with measurement of liver stiffness (LS) and controlled attenuation parameter (CAP). Subsequently, the 212 prediabetic patients were enrolled into a prospective randomized interventional study: 104 were allocated to Mediterranean diet alone while 108 followed Mediterranean diet plus supplementation with silymarin (a flavonolignan complex isolated from Silybum marianum and Morus alba). The administered silymarin dose was 210 mg twice daily for 6 months. Clinical and instrumental evaluations were repeated at the end of the 6 month-study period. Prediabetics were genotyped for patatin like phospholipase domain containing 3 (PNPLA3). Results In the case-control study, 29% of prediabetic patients have significant fibrosis defined as LS ≥ 7.9 kPa vs only 3% of controls (p < 0.001). PNPLA3 genotype CG/GG are significantly associated with significant fibrosis LS ≥ 7.9 relative to CC genotype χ2(1) = 76.466, p < 0.001. Binomial regression analysis shows that increase in BMI, ALT and AST are significantly associated with increased likelihood of significant fibrosis (χ2(7) = 191.9, p < .001) prior to intervention. In the randomized interventional study, prediabetics following Mediterranean diet alone (group 1) experienced a significant regression of fibrosis and decrease in ALT, HbA1c, FBS after 6 months (p < 0.001); similar findings were observed in patients following Mediterranean diet plus silymarin regimen (group 2); group 2 had a significant decrease in HbA1c relative to group 1 (95% CI: 37.8–38.6 vs 39.5–40.3, p < 0.001). Conclusion PNPLA3 genotype CG/GG and elevated BMI are the major predictors of significant fibrosis in prediabetic patients prior to intervention in this study. Mediterranean diet either alone or with silymarin treatment for 6 months leads to significant regression of liver damage and improvement of the glycemic profile in prediabetic patients. Yet, as combination treatment of silymarin with Mediterranean diet shows significant reduction of HbA1c when compared to diet alone, this suggests that silymarin may exert an independent anti-glycemic action.

show abstract

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

2021

Eat Weight Disord

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the past years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato, the Società Italiana di Diabetologia and the Società Italiana dell'Obesità reviewed current knowledge on NAFLD. The quality of the published evidence is graded, and practical recommendations are made following the rules and the methodology suggested in Italy by the Centro Nazionale per l'Eccellenza delle cure and Istituto Superiore di Sanità. Whenever possible, recommendations are placed within the context the Italian Healthcare system, with reference to specific experience and local diagnostic and management resources. Level of evidence Level of evidence of recommendations for each PICO question were reported according to available evidence.

show abstract

Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients

Cited by 22 publications

References 25 publications

Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

Fibroscan for Assessment of Non Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients in Tanta University Hospital

Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Contact Info

Product

Resources

About